109Single-agent tacrolimus for prophylaxis of acute graft-versus-host disease after related allogeneic peripheral blood stem cell transplantation: A phase II study  by Schwartz, J.E. et al.
Poster  P resentat ions  - Sess ion  I 
the graft have resulted in poor engraftment and elevated isease 
recurrence. Separation of the T-cell effects supporting engraft- 
ment of hematopoietic stem/progenitor cells (HSPC) from their 
effects leading to GVHD could increase the use of this treatment 
while broadening the pool of acceptable donors. To determine if
CD8 T-cell facilitation of engraftment is limited to abrogation of 
the host's resistance, we utilized a routine syngeneic model acking 
host resistance to donor HSPC. 2x106 GFP + C57BL/6 (B6) T-cell 
depleted bone marrow cells (BM-TCD) were transplanted alone 
or in the presence of 2x106 highly enriched B6 CD8 T-cells into 
10.0 Gy lethally irradiated B6 mice. Recipient BM was harvested 
seven days later and incubated separately in IL-3 supplemented 
semi-solid culture medium. Recipients of BM-TCD and CD8 T- 
cells showed significantly greater donor colonies by fluorescent 
microscopy than recipients of only BM-TCD. It appears that 
CD4 T-cells may not share this early facilitating capacity, as illus- 
trated by an initial experiment in which day 7 post-BMT donor 
colonies were clearly not augmented by supplementing BM-TCD 
with highly enriched CD4 T-cells. Notably, the increased progen- 
itor activity in the presence of CD8 T-cells was not observed in 
recipients receiving 5.5 Gy sublethal conditioning. The require- 
ment for stronger irradiation is not apparently due to differential 
T-cell activation; GFP + B6 donor CD8 T-cells, harvested three 
days post-BMT from either 5.5 or 10.0 Gy irradiated B6 recipient 
spleen and BM, did not differentially express CD69 (not detect- 
ed), CD25 (not detected), or Sca-1 (expressed) by flow cytometric 
analysis. The ability of donor CD8 T-cells to support increased 
progenitor activity in a syngeneic BMT model suggests that their 
role in engraftment is not limited to abrogation of the host's 
resistance. Further elucidation of this early facilitating capacity 
could lead to new BMT regimens upporting engraftment with a 
decreased risk of GVHD, as well as a greater understanding of T- 
ceil biology. 
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PREVENTION OF PLATELET TA-GVHD BY USE OF INTERCEPT 
BLOOD SYSTEM 
Lin, L.; Cow,ash, L. Ceras Corporation, Comord, CA. 
Contaminating T-cells in platelet concentrates (PC) may ini- 
tiate TA-GVHD.  This study evaluated the efficacy of the 
INTERCEPT Blood System for platelets (150 btM amotosalen 
HC1 and 3 Joules/cmeUVA) for prevention of platelet TA- 
GVHD. Using molecular (DNA binding and PCR) and cellu- 
lar (LDA and ELISA) assays we have demonstrated a >105.4- 
fold reduction of viable T-cel ls in PC and inhibit ion of 
cytokine synthesis (IL8, IL lb)  during storage of INTER-  
CEPT platelets. In addition, we have demonstrated the effect 
of treatment on the development of GVHD in two in vivo 
murine transfusion models. In one model, transfusion of 108 
splenocytes from homozygous parent (A) donors into 
immunocolnpetent heterozygous hybrid (B6AF1) recipients 
resulted in acute TA-GVHD as evidenced by splenomegaly, 
donor T-cell engraftment (35%), immune suppression (4-fold 
reduction in thymocyte count), histologic evidence of GVHD 
in liver, spleen, bone marrow, and skin with transient pancy- 
topenia, progressive weight loss, hunching, and mortality. In 
contrast, B6AF1 recipients of treated splenocytes remained 
healthy and had no evidence of GVHD as judged by the same 
parameters. In a second model, transfusion recipients were 
immunocompromised. After total body irradiation with 1100 
cGy of gamma, CBA mice were reconst ituted by T-cel l -  
depleted bone marrow (BM) transplantation from B10.BR 
donors. Presence of 0.5 x 106 to 3.0 x 106 splenic T-cells in 
the BM induced acute GVHD in the recipients as evidenced 
by ruffled fur, hunching, weight loss, thymus hypoplasia, his- 
tological lesions in liver and skin, and mortality (80% to 
90%). in contrast, gamma irradiated CBA who were trans- 
planted with BM containing treated, 3 x I06 to 30 x 106 
splenic T-cells remained free of signs of GVHD. Therefore, 
use of the INTERCEPT Blood System for platelets to inacti- 
vate high titers of pathogenic viruses and bacteria in PC has 
the potential to prevent TA-GVHD associated with human 
PC transfusion. 
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A ROLE FOR THE P75 BUT NOT THE P55 TNF~ RECEPTOR IN THE 
DEVELOPMENT OF IDIOPATHIC PNEUMONIA SYNDROME AFTER 
ALLOGENEIC STEM CELL TRANSPLANTATION 
Cooke, K.R.I; Olkiewic~, 1( I; Erieksol~, N.1; HildebT~amlr, G J; Li'a, C.:; 
Ferrm:a, ff.L. z 1. Pediatrics, Braze 3/lmT-ow Tramp~am Program, Uni- 
versity of Michigan Cancer Center, Ann Arbor, MI; 2. UJzive*'sity of 
Florida, College of 3/iedici~ze, Gaimville, FL. 
Idiopathic pneumonia syndrome (IPS) is a major complication 
of allogeneic SCT and recent studies have demonstrated a casual 
role for TNFo~ in the development of this process. The inflam- 
matory effects of TNFc~ are transduced via signaling through 
either the p55 or p75 TNF receptor (TNFR). Although the p55 
receptor is believed to be more important in mediating TNF- 
induced cytotoxicity, the p75 TNFR also contributes to this 
process both via its own signaling mechanism and by regulating 
the access of TNFc~ to the p55 TNFR. We examined the contri- 
bution of each TNFR to the development of IPS by using an 
established routine SCT model across minor histocompatibility 
differences (LP --+ B6). Wild type (wt) B6 mice or B6 animals 
deficient in either the p55 (p55 -/-) or p75 (p75 -/-) receptor 
were lethally irradiated and received BM and T cells from either 
allogeneic (LP/J) or syngeneic (B6) donors. Mice were subse- 
quently monitored for the development of IPS and systemic 
GVHD. At week 6 after SCT, examination of coded lung samples 
demonstrated that p75 -/- recipients of allogeneic SCT devel- 
oped significantly less lung histopathology compared to wt con- 
trois (1.9 _+ 0.3 vs. 6.4 _+ 0.7; p > 0.0I). These findings were asso- 
ciated with reductions in BAL fluid total cellularity (1.l _+ 0.2 x 
106 vs. 2.5 _+ 0.5 x 106; p < 0.01) and CD8+ T lymphocytes. 
However, BAL fluid TNF~ levels were comparable between both 
allogeneic groups, p75 -/- allogeneic SCT recipients also demon- 
strated reduced target organ GVHD (liver and intestine; p < 
0.05) but not systemic GVHD (mortality, clinical score) com- 
pared to wt controls. Although p55 -/- animals had a significant 
survival advantage compared to wt controls, the absence of the 
p55 receptor had no effect on the severity of IPS or target organ 
GVHD. These data demonstrate a role for the p75 TNFR in the 
development of IPS in this SCT model and support the hypothe- 
sis that disruption of TNFR:TNFc~ receptor:ligand interactions 
may represent a novel strategy to prevent or treat acute lung 
inju W in the clinical setting. Furthermore, these findings reveal 
differential effects of the p55 and p75 TNFRs in GVHD induc- 
tion; absence of the p55 TNFR in allogeneic SCT recipients is 
associated with improved survival, however the p75 receptor 
appears to be critical to target organ damage that develops in sur 
viving animals. 
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SINGLE-AGENT TACROLIMUS FOR PROPHYLAXIS OF ACUTE GRAFT- 
VERSUS-HOST DISEASE AFTER RELATED ALLOGENEIC PERIPHERAL 
BLOOD STEM CELL TRANSPLANTATION: A PHASE II STUDY 
Schwartz, J.E/; BuchBarker, D.M/; Grif]k~, D.L/; de k/Iagalhaes- 
Silvelwlml, 111.2; Donnenberg, A.D/; Rybka, kV.B.S; Ball, E.D.4; Yea- 
ge'~, A.M. 1 1. University of Pittsburgh, Pittsbut'gh, PA; 2. University of 
Iowa, Iowa City, L4; 3. Milton S. Hershey Medieal Cemer, Hershey, 
PA; 4. University of GdiJb~vzia San Diego, San Diego, CA. 
Single-agent tacrolimus (TAC; FK-506) is effective prophylmvis 
for acute graft-versus-host disease (GVHD) after allogeneic bone 
marrow transplantation (BMT) from HLA-matched related 
donors (Fay JW et al., Blood 1996; 87(8): 3514-9) but has not 
been previously evaluated as single-agent GVHD prophylaxis 
after allogeneic peripheral blood stem celI transplantation 
(PBSCT). We evaluated single-agent TAC in 31 patients (median 
age, 43 years; range: 19-60)with ematologic malignancies (30) or 
common variable immunodeficiency (1) who received PBSCTs 
from related 5/6 (2) or 6/6 (29) HLA matched onors. All patients 
received a preparative regimen of oral busulfan (16mg/kg) and 
cyclophosphamide (120mg/kg). Tacrolimus was initiated at 0.03 
mg/kg/d intravenously, and the dosage was adjusted to maintain 
TAC levels between 5-15 ng/ml. Patients were continued on oral 
maintenance TAC until 6 months after PBSCT. Nine patients 
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(29%) developed a thrombotic thrombocytopenic 
purpuraAnicroangiopathic hemolytic anemia syndrome or an 
acute hemolytic reaction that was treated with plasmapheresis or 
red cell exchange. Twenty-one of 30 (70%) evaluable patients 
developed grade II-IV acute GVHD. Of these, 62% had grade 
III-IV acute GVItD. Sixteen of 21 (76%) evaluable patients, 
developed chronic GVHD with 63% of those patients having 
extensive chronic GVHD. The day 100 survival was 68%. Ten 
patients are alive at a median of 67.6 months (range: 45.2-82.3), 
for an overall survival of 32%. These results indicate that, in con- 
trast to its effects after allogeneic BMT, single-agent tacrolimus 
does not adequately prevent GVHD after related allogeneic 
PBSCT. 
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PHASE II STUDY OF DENILEUKIN DIFTITOX (ONTAK) IN THE 
TREATEHENT OF STEROID RESISTANT ACUTE GRAFT VERSUS HOST 
DISEASE (AGVHD) 
Shat~g',~nes~, P.; Bachier, C.; G'dmley, M.; LeMaid'tre, C.F. Texas 
Transplant lnstitute, San Anto~lio, TX. 
AGVHD is one of the pricipal complications of allogeneic 
heluatopoietic stem cell transplantation. Ontak is a recombi- 
nant DNA derived cytotoxic fusion protein designed to direct 
the cytocidal action of diphtheria toxin to cells with high affin- 
ity of the IL-2 receptor. We designed a phase II trial to exam- 
ine the Ontak in patients (pts) with steroid resistant AGVHD. 
Steroid resistance was defined as treatment with 2mg/kg of 
methylprednisolone and progressive disease after 3 days or sta- 
ble disease after 7 days. Ontak treatment was 4.Smcg/kg/day 
IV for 5 days followed by the same dose weekly for 4 weeks. 
Four pts have been treated to date. Pt #I had stage 3 skin and 
stage 4 GI AGVHD that improved to stage 1 skin and stage 1 
GI by day 5 of the Ontak. Ontak was held in this pt because of 
a low albumin and fluid retention. GVHD recurred 4 weeks 
after Ontak was held and, despite treatment with inflixamab, 
GVHD progressed and the pt died of psuedonmnas sepsis. Pt 
#2 had stage 3 skin AGVHD that responded completely by day 
5 of the Ontak and finished 3 of the 4 weekly treatments, with 
the last treatment held for pancytopenia. Pt #3 had stage 4 GI 
and conjuctival AGVHD that completely resolved by day 5 of 
Ontak and finished all treatments. Pt #4 had stage 4 liver, 3 
skin, and 4 GI AGVHD that progressed after the first 5 day 
infusion of Ontak and was taken off study and treated with 
inflixilnab with an improvement to stage 3 liver, 0 skin, and 4 
GI AGVHD. Pt #4 had a generalized tonic-clonic seizure on 
day 2 of the Ontak infusion that was felt to be related to 
cyclosporine and completed the Ontak infusion with no fur 
ther neurologic sequalae. Pt #4 also developed isseminated 
adeuovirus. Pts #2 and #3 had grade III hematologic toxicity 
that was felt to be multifactorial and both also had bacterial 
upper respiratory tract infections that were treated and 
resolved. Patient #3 had CMV reactivation that was pre-emp- 
tively treated with valgancyclovir and resolved. Pts #2 and #3 
are both greater than 100 days from the start of the Ontak 
treatment and have been tapered to less than 0.5mg/kg or 
steroids while remaining on FK506 with no evidence of 
AGVHD. In conclusion, the low dose of Ontak used in this 
study appears active in AGVHD with acceptable toxicity. Fur- 
ther study to assess infection risk, response rates, and patient 
survival are warranted. .... 
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SELECTIVE DEPLETION OF HUMAN GVH-REACTIVE T-CELLS BY 
ANTI-CD95 MEDIATED ACTIVATION-INDUCED CELL DEATH OR VIA 
THE T-CELL ACTIVATION ANTIGEN CD69 FOR PREVENTING GRAFT- 
VERSUS-HOST DISEASE IN ALLO-BMT 
Norm, M.; Tnbbe, i.; Hnber, C.; Hartwig, U.F. Dept. of Hematology, 
Mamz, GelwzaJTy. 
Depletion of T-cells from allogeneic bone marrow transplants 
(BMT) ameliorates GvHD but is associated with impaired 
engraftment, inmmnosuppression, a dabrogation of the benefi- 
cial graft-versus-leukemia effect (GvL). We, therefore, explored 
the possibility of separating alloreactivity from T lymphocytes 
mediating GvL-responses x vivo by selective depletion of GvH- 
reactive T-cells using CD95/CD178-mediated activation induced 
cell death (MCD) or via the T-cell activation antigen CD69. T- 
cells purified from human PBMC were stinmlated with fully-mis 
matched stimulators in an allogeneic mixed lymphocyte culture 
(MLC) in the presence of agonistic anti-CD95 mAb. Specificity of 
depletion was tested by consecutively monitoring CMV-pp65 spe- 
cific T-cells present in PBMC from seropositive donors before 
and after MCD. As reported earlier in a murine model, prolifera- 
tive responses ofalloreactive T-cells were reduced 65-90% in the 
presence of anti-CD95 reagents depending on the mAb used. 
ELISpot analysis revealed the retainment ofpp65-specific T-cells 
in the residual allogeneic T-lymphocyte population comparable to 
frequencies detected in normal controls. In comparative studies, 
elimination of alloreactive specificities by imnmnomagnetic sepa- 
ration using the T-cell activation marker CD69 resulted in 3 sub- 
sets ofT-cells. Restimulation ofCD69- cells (> 98%) as well as the 
CD69 + population and the CD69 dull cells retrieved from the wash- 
fraction with 1st party stimulators esulted in a substantial reduced 
proliferation of the CD69- cells as compared to he positive sub- 
set. The CD69 d~ll T-lymphocytes also showed residual alloreactiv- 
ity. Interestingly, monitoring for pp65-reactive T-cells by 
ELISpot analysis indicated that the majority of pp65-specific T- 
cells appeared to be enriched in the CD69 '1"11 population. Further 
studies on the efficacy, specificity and potential of retained allo- 
geneic T-cells to respond to l~mwn leukemia associated antigens 
in HLA-naislnatched as well as HLA-lnatched settings are in 
progress and will be discussed. 
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SERUM CYTOKINE PROFILES OF PATIENTS WITH ACUTE GVHD 
TREATED WITH METHYLPREDNISOLONE ALONE OR IN COMBINA- 
TION WITH INFLIXIMAB ARE DIFFERENT 
Lee, B.; Couvie/, D.; Shen, D.; Hhlze, L.; C,Oam, plin, R.; Re~tt, e~7, J.M. 
M.D.Anderson Uancer Center, Houston, TX. 
Graft-versus-host disease (GVHD) is a major problem for recip- 
ients of allogeneic blood and marrow transplantation. GVHD, 
mediated by TNF-alpha produced by activated mononuclear cells, 
can be treated with methylprednisolone (NIP) or in combination 
with Infli.'dmab (I), a chimeric human/lnouse anti-TNF antibody 
that interferes with the activity of TNF-alpha. Moreover, as acute 
GVHD (aGVHD) is linked to increases in the levels of inflamma- 
tory cytokines, we hypothesized that there would be a decrease in
inflammatory cytokines as patients achieved a complete response 
following treatment for aGVHD. Therefore, we collected sera 
from 52 patients with aGVHD who were randomized to one of 
two treatment arms to receive either methylprednisolone (MP) or 
MP plus Infli~mab (MP+I) once a week for 4 weeks. We meas- 
ured serum levels of IL-2, IL-6, IL-10, IL-12, TNF-alpha, and 
IFN-gamma pre-treatment and at weekly intervals thereafter for 5 
weeks on a subset of patients with aGVHD. We analyzed CTtokine 
data for 10 MP and 10 MP+I patients. The levels of IL-6, IL-10, 
, IL-12, and IFN-gamma before and after treatment were similar 
for both groups. The profiles of IL 2 and TNF2alpha levels over 
time however were different for the 2 groups. The levels of these 
cytokines in the MP+I group peaked in the first wo weeks of 
treatment and declined thereafter. Conversely, the levels of IL-2 
and TNF-alpha in the MP group were low in the first two weeks 
of treatment and increased thereafter. These preliminal T data sug- 
gest that there may be differences in the profiles of IL-2 and 
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